跳至主要内容
临床试验/EUCTR2019-002844-25-DK
EUCTR2019-002844-25-DK
进行中(未招募)
1 期

Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty. The RECIPE Randomized Clinical Trial - RECIPE

Daniel Hägi-Pedersen0 个研究点目标入组 1,060 人2019年9月26日
相关药物Dexa-Ratiopharm

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Daniel Hägi-Pedersen
入组人数
1060
状态
进行中(未招募)
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2019年9月26日
结束日期
待定
最后更新
4年前
研究类型
Interventional clinical trial of medicinal product
性别
All

研究者

发起方
Daniel Hägi-Pedersen

入排标准

入选标准

  • Scheduled for elective, unilateral, primary total hip arthroplasty
  • BMI \> 18 and \< 40
  • Negative urine HCG pregnancy test and use of anti\-conception for women in the fertile age
  • Give written informed consent to participate in the trial after having fully understood the contents of the protocol and restrictions
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 424
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range 636

排除标准

  • Patients who cannot cooperate with the trial
  • Concomitant participation in another trial involving medication
  • Patients who cannot understand or speak Danish
  • Patients with allergy to medication used in the trial
  • Patients with daily use of high dose opioid (\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other
  • opioids including methadone and transdermal opioids.
  • Patients with daily use of systemic glucocorticoids (within 3 months before the trial)
  • Contraindications against ibuprofen or paracetamol, for example previous ulcer, known heart failure, known liver failure, or known renal failure
  • (eGRF \< 60 ml/kg/1,73m2\), known thrombocytopenia (\< 100 x 109/l); or against treatment with glucocorticoids
  • Dysregulated diabetes (investigator’s judgement)

结局指标

主要结局

未指定

相似试验